155 related articles for article (PubMed ID: 8080010)
1. Long-term renal effect of cisplatin in man.
Brillet G; Deray G; Jacquiaud C; Mignot L; Bunker D; Meillet D; Raymond F; Jacobs C
Am J Nephrol; 1994; 14(2):81-4. PubMed ID: 8080010
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
3. Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment.
Tirelli AS; Colombo N; Cavanna G; Mangioni C; Assael BM
Eur J Clin Pharmacol; 1985; 29(3):313-8. PubMed ID: 3908127
[TBL] [Abstract][Full Text] [Related]
4. The long-term effect of cisplatin on renal function.
Fjeldborg P; Sørensen J; Helkjaer PE
Cancer; 1986 Nov; 58(10):2214-7. PubMed ID: 3756770
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
6. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
7. [Studies of enzymuria and proteinuria: Report 2; Relationship between glomerular filtration rate and urinary enzymuria and proteinuria].
Yasumoto R; Tanaka S; Kawashima H; Kakinoki K; Iseki T; Umeda M; Tanabe S; Nishisaka N; Asakawa M
Hinyokika Kiyo; 1989 Jul; 35(7):1125-8. PubMed ID: 2478007
[TBL] [Abstract][Full Text] [Related]
8. Changes in urinary excretion of endothelin-1-like immunoreactivity in patients with testicular cancer receiving high-dose cisplatin therapy.
Takeda M; Komeyama T; Tsutsui T; Mizusawa T; Go H; Hatano A; Tanikawa T
Am J Kidney Dis; 1994 Jul; 24(1):12-6. PubMed ID: 8023817
[TBL] [Abstract][Full Text] [Related]
9. Long-term nephrotoxicity in adult survivors of childhood cancer.
Dekkers IA; Blijdorp K; Cransberg K; Pluijm SM; Pieters R; Neggers SJ; van den Heuvel-Eibrink MM
Clin J Am Soc Nephrol; 2013 Jun; 8(6):922-9. PubMed ID: 23411430
[TBL] [Abstract][Full Text] [Related]
10. Cystatin C--a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy.
Benöhr P; Grenz A; Hartmann JT; Müller GA; Blaschke S
Kidney Blood Press Res; 2006; 29(1):32-5. PubMed ID: 16582575
[TBL] [Abstract][Full Text] [Related]
11. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.
Funakoshi Y; Fujiwara Y; Kiyota N; Mukohara T; Shimada T; Toyoda M; Imamura Y; Chayahara N; Tomioka H; Umezu M; Otsuki N; Nibu K; Minami H
Cancer Chemother Pharmacol; 2016 Feb; 77(2):281-8. PubMed ID: 26791871
[TBL] [Abstract][Full Text] [Related]
12. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.
Ansquer JC; Dalton RN; Caussé E; Crimet D; Le Malicot K; Foucher C
Am J Kidney Dis; 2008 Jun; 51(6):904-13. PubMed ID: 18501783
[TBL] [Abstract][Full Text] [Related]
13. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
Ujiie T; Maruta H; Ito N
Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
[TBL] [Abstract][Full Text] [Related]
14. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats.
Nakamura T; Kokuryo T; Hashimoto Y; Inui KI
J Pharm Pharmacol; 1999 Feb; 51(2):227-32. PubMed ID: 10217324
[TBL] [Abstract][Full Text] [Related]
15. Comparison of renal function parameters in the assessment of cis-platin induced nephrotoxicity.
Verplanke AJ; Herber RF; de Wit R; Veenhof CH
Nephron; 1994; 66(3):267-72. PubMed ID: 7910667
[TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).
Ikeda H; Nagashima K; Okumura H; Takahashi A; Matsuyama S; Nagamachi Y
Eur J Surg Oncol; 1988 Feb; 14(1):17-20. PubMed ID: 3278937
[TBL] [Abstract][Full Text] [Related]
17. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.
Daugaard G; Rossing N; Rørth M
Cancer Chemother Pharmacol; 1988; 21(2):163-7. PubMed ID: 3280153
[TBL] [Abstract][Full Text] [Related]
18. Cumulative renal tubular damage associated with cisplatin nephrotoxicity.
Goren MP; Wright RK; Horowitz ME
Cancer Chemother Pharmacol; 1986; 18(1):69-73. PubMed ID: 2875808
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the resistive index by Doppler ultrasound and kidney function and histology.
Ikee R; Kobayashi S; Hemmi N; Imakiire T; Kikuchi Y; Moriya H; Suzuki S; Miura S
Am J Kidney Dis; 2005 Oct; 46(4):603-9. PubMed ID: 16183414
[TBL] [Abstract][Full Text] [Related]
20. Cystatin C, Beta2 Microglobulin, N-Acetyl-beta-D-glucosaminidase, Retinol-Binding Protein, and Endothelin 1 Levels in the Evaluation of Sickle Cell Disease Nephropathy.
Unal S; Kotan C; Delibas A; Oztas Y
Pediatr Hematol Oncol; 2015 May; 32(4):250-7. PubMed ID: 23987825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
